| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
Using the non-small cell lung cancer cell lines, the sensitizing effect of carbon ion beam and anticancer agent was investigated. As a result of in vitro experiments, it was confirmed that sensitizing effect was almost equal or a little lower than that of X rays. This suggested the combination with carbon ion radiotherapy and anticancer drugs (carboplatin and paclitaxel) for non-small cell lung cancer are useful. As a clinical approach, we studied the difference in dose distribution between X-rays and carbon ion beams for locally advanced lung cancer. Compared with X-ray, carbon ion radiotherapy provides a more homogeneous target dose and a lower dose to organs at risk than X-ray radiotherapy for Stage IIIA non-small cell lung cancer.
|
